Showing 3271-3280 of 5231 results for "".
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signali
- Cutera Recognized by 50/50 Women on Boards for Gender-Balanced Board of Directorshttps://practicaldermatology.com/news/cutera-recognized-by-5050-women-on-boards-for-gender-balanced-board-of-directors/2461315/The 50/50 Women on Boards recognized Cutera for having a gender-balanced board. With four women directors, holding 50 percent of its corporate board seats, Cutera, Inc. is one of only 8 percent (just 241) of Russell 3000 companies with a gender-balanced board. &ldq
- Aesthetics Biomedical Adds to Leadership Team to Fuel Growth Trajectoryhttps://practicaldermatology.com/news/aesthetics-biomedical-adds-to-leadership-team-to-fuel-growth-trajectory/2461280/In an ongoing efforts to meet the increasing demand for its aesthetic products and distribution growth, Aesthetics Biomedical Inc. (ABM), is continuing to build its executive team with the recent hires of industry experts Derek Harmon as Vice President of U.S. Sales and Don Selvey, NMD, MS as Vic
- Physician Growth Partners Advises MetroDerm PC in Partnership with United Derm Partnershttps://practicaldermatology.com/news/physician-growth-partners-advises-metroderm-pc-in-partnership-with-united-derm-partners/2461277/Physician Growth Partners (PGP) has advised
- Novan's Berdazimer Gel Performs Well in Phase 3 for Molluscum: Studyhttps://practicaldermatology.com/news/novans-berdazimer-gel-performs-well-in-phase-3-for-molluscum-study/2461269/Berdazimer gel, 10.3% from Novan, Inc., significantly out-performed placebo for the treatment of molluscum, according to results of the B-SIMPLE 4 pivotal Phase 3 clinical study published in JAMA Dermatology</
- Cynosure's New Tempsure eyeEnvi Handpiece Offers Improved Function and Greater Comforthttps://practicaldermatology.com/news/cynosures-new-tempsure-eyeenvi-handpiece-offers-improved-function-and-greater-comfort/2461258/Cynosure has added a new Tempsure eyeEnvi handpiece to its portfolio. Featuring innovative ergonomic pencil grip design and lighter piston tension required to activate the treatment, the company says the new handpiece is more comfortable for patients and providers, heating thinner tissue mor
- SCUBE3 May Stimulate Hair Growthhttps://practicaldermatology.com/news/scube3-may-stimulate-hair-growth/2461254/University of California, Irvine-led researchers have discovered that a signaling molecule called SCUBE3 potently stimulates hair growth and may offer a therapeutic treatment for androgenetic alopecia, according to a study published in
- NYC PrideFest: Galderma Aesthetics to Participatehttps://practicaldermatology.com/news/nyc-pridefest-galderma-aesthetics-to-participate/2461249/Galderma is participating in New York City's official LGBTQIA+ Pride (NYC Pride) event. This month marks the official launch of Restylane's "XpresYourself" communications campaign, which gives a nod to Restylane's XpresHAn Technology™, a u
- Nu Skin Kicks Off Its Global Day of Service with Projects for Childrenhttps://practicaldermatology.com/news/nu-skin-kicks-off-its-global-day-of-service-with-projects-for-children/2461233/Nu Skin is hosting its 19th annual Force for Good Day to support its global humanitarian efforts. To celebrate the company's founding and to give back to local communities, each Nu Skin region sets aside a day to participate in service projects as part of its mission to b
- Timber's Topical Isotretinoin Gets Breakthrough Therapy Designation for CIhttps://practicaldermatology.com/news/timbers-topical-isotretinoin-gets-breakthrough-therapy-designation-for-ci/2461217/TMB-001, a topical isotretinoin formulated using patented IPEG™ delivery system from Timber Pharmaceuticals, Inc. has been granted Breakthrough Therapy designation by FDA for the treatment of congenital ichthyosis (CI). Timber is developi